Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Site Search
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Bill Would Remove Financial Penalties for Participating in Research Studies
CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
As the Senate considers adding repeal of the Affordable Care Act's (ACA) individual mandate to its tax reform package, a group of 16 nonpartisan patient and consumer groups issued a statement on last week's Congressional Budget Office (CBO) report.
Un diagnóstico de fibrosis quística no debe descalificar a una persona para recibir atención que pueda salvarle la vida.
Patient and provider groups urge the Senate to work together in a bipartisan fashion to ensure that Americans have access to affordable health care.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.